1) BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+

Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each

2) LinkedIn post: Another Atlas Global WiFI patent bites the dust

TP-Link prevailed in the Federal Patent Court of Germany. Out of five patents-in-suit, four have been revoked and the fifth will be the subject of an opposition hearing in November, with a negative preliminary non-binding opinion already having issued.

3) NPEs file as few as 10% of ITC Section 337 complaints: agency counsel 

Between 70% and 90% of ITC investigations are initiated by non-NPEs, with those numbers generally increasing, while there is a notable shift in the NPEs that do file complaints toward being more innovation-focused.

4) Chinese court enforces $73 million U.S. judgment: door opens for more foreign order enforceability, including UPC

A Chinese order enforcing a U.S. judgment based on reciprocity could mean the Unified Patent Court will no longer require Chinese companies to pay collateral, with the increased possibility that UPC judgments will now be enforced in China too.

5) Access Advance extends early-bird period for video streaming patent license to September 30, 2025: service announcement

The early-bird period for implementers takikng a license to Access Advance’s Video Distribution Pool has been extended to September 30.

6) Gallium nitride patent wars: Munich I Regional Court grants Infineon second injunction against Innoscience

The pendulum has swung back in favor of Infineon in its long-running dispute against Innoscience over gallium nitride technology.